Biotech | May 02, 2022
Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical
Avacc 3 has significant advantages over existing whooping cough vaccines
Avacc 3 has significant advantages over existing whooping cough vaccines
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
HTL will build, validate and operate a botulinum manufacturing facility in the US
Subscribe To Our Newsletter & Stay Updated
